Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS: In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an additional 10 weeks. The primary end point, the proportion of patients who had adequate relief of global IBS symptoms, and the key secondary end point, the proportion of patients who had adequate relief of IBS-related bloating, were assessed weekly. Adequate relief was defined as self-reported relief of symptoms for at least 2 of the first 4 weeks after treatment. Other secondary end points included the percentage of patients who had a response to treatment as assessed by daily self-ratings of global IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during the 4 weeks after treatment and during the entire 3 months of the study. RESULTS: Significantly more patients in the rifaximin group than in the placebo group had adequate relief of global IBS symptoms during the first 4 weeks after treatment (40.8% vs. 31.2%, P=0.01, in TARGET 1; 40.6% vs. 32.2%, P=0.03, in TARGET 2; 40.7% vs. 31.7%, P<0.001, in the two studies combined). Similarly, more patients in the rifaximin group than in the placebo group had adequate relief of bloating (39.5% vs. 28.7%, P=0.005, in TARGET 1; 41.0% vs. 31.9%, P=0.02, in TARGET 2; 40.2% vs. 30.3%, P<0.001, in the two studies combined). In addition, significantly more patients in the rifaximin group had a response to treatment as assessed by daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools. (Funded by Salix Pharmaceuticals; ClinicalTrials.gov numbers, NCT00731679 and NCT00724126.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Placebo-controlled studies of antibiotic (rifaximin) treatment in FGIDs and IBS have demonstrated significant reduction in bloating scores with rifaximin compared to placebo150–152.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A short course of a non-absorbable antibiotic such as rifaximin has been shown to moderately improve the symptoms of irritable bowel syndrome (IBS), particularly bloating and flatulence.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, it is likely that patients may require repeated courses of therapy, as trial evidence suggests the benefit diminishes by 12 weeks.189”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The sample size calculation was based on a one-sided α level of 0·0125 to account for two primary end points, an assumed placebo response rate of 40 % and a treatment difference of 10 % in responder rates based on previously published studies( 23 , 28 ). Further, accounting for a potential 10 % dropout rate and three interim analyses, 580 subjects in each group were required, totalling to 1740 sub”
From Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial (2015) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, treatments that change the microbiota, such as antibiotics or fecal microbiota transplant, 19,20 may be bene fi cial in a subset of patients with IBS.”
From Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis (2023) · cites this paper as [19]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Self-citationPimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669
Self-citationSmall intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00004 · Cited by 466
Self-citationSharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Attar, A., Flourié, B., Rambaud, J., Franchisseur, C., Ruszniewski, P., & Bouhnik, Y. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70336-7 · Cited by 234
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Self-citation
Research works printed but not linked: 1
- El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health- related quality of life. Rev Gastroenterol Disord 2003;3:Suppl 2:S3-S11.
Cited by
Items 301–400 of 1,000
Existing and emerging therapies for managing constipation and diarrhea
Bharucha, A. E., Wouters, M. M., & Tack, J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.10.015 · Cited by 43
“7%) and also at 10 weeks posttreatment.[19] Adequate relief was defined by an affirmative response to the question: “In regard to all your symptoms of IBS, as compared with the way you felt before you started the study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms?” Subsequently, t…”
BackgroundThe Rationale and Clinical Effectiveness of Probiotics in Irritable Bowel Syndrome
Ringel, Y., & Ringel-Kulka, T. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31822d32d3 · Cited by 44
Self-citationDiagnostic criteria in IBS: useful or not?
Mearin, F., & Lacy, B. E. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01992.x · Cited by 44
Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use
Saadi, M., & McCallum, R. W. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312472008 · Cited by 44
“Follow-up work in this area has begun to demonstrate associated factors between gut bacteria and IBS that may explain the different types of IBS [Pimentel and Lezcano, 2007].”
BackgroundTuteja, A. K., Talley, N. J., Stoddard, G. J., & Verne, G. N. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5344-5 · Cited by 42
Microbiota in Irritable Bowel Syndrome and Endometriosis: Birds of a Feather Flock Together—A Review
Salmeri, N., Sinagra, E., Dolci, C., Buzzaccarini, G., Sozzi, G., Sutera, M., Candiani, M., Ungaro, F., Massimino, L., Danese, S., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11082089 · Cited by 49
“It has been postulated that Rifaximin may modulate the gut microbiota, reducing the burden of bacteria responsible for micro-inflammation and immune responses [101].”
Pathophysiology, evaluation, and treatment of bloating: hope, hype, or hot air?
Lacy, B. E., Gabbard, S. L., & Crowell, M. D. (2011) · Europe PMC (PubMed Central) · Cited by 62
Lacy, B. E. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12716 · Cited by 47
Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders
Camilleri, M., Bueno, L. P., Andresen, V., Ponti, F. D., Choi, M., & Lembo, A. J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.029 · Cited by 49
Self-citationRifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE)
Cuomo, R., Barbara, G., & Annibale, B. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.01.164 · Cited by 47
Biologic properties and clinical uses of rifaximin
DuPont, H. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.546347 · Cited by 44
“Low levels of PXR may be associated with activity in both Crohn’s disease and ulcerative colitis [14,15], which may explain Primary and potential mechanisms/activities Biologic and clinical effectsBioavailability HE: Hepatic encephalopathy; IBS: Irritable bowel syndrome; MIC: Minimal inhibitory concentration.”
BackgroundInfluentialKönig, J., & Brummer, R. J. (2014) · Beneficial Microbes · doi:10.3920/bm2013.0033 · Cited by 42
“In addition, rifaximin was effective in retreating patients that presented with a relapse after the first antibiotic treatment, and it does not seem to provoke clinical resistance (Pimentel et al. , 2011b; Yang et al. , 2008).”
Treatment of Dientamoeba fragilis in Patients with Irritable Bowel Syndrome
Engsbro, A. L., Stensvold, C. R., Nielsen, H. V., & Bytzer, P. M. (2012) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2012.11-0761 · Cited by 42
Aspergillus: Biodiversity, Ecological Significances, and Industrial Applications
Abdel-Azeem, A. M., Abdel-Azeem, M. A., Abdulhadi, S. Y., & Darwish, A. M. G. (2019) · Fungal biology · doi:10.1007/978-3-030-10480-1_4 · Cited by 58
Quigley, E. M. M., Markinson, L., Stevenson, A., Treasure, P., & Lacy, B. E. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17310 · Cited by 46
Immunological Biomarkers in Postinfectious Irritable Bowel Syndrome
Pike, B. L., Paden, K. A., Alcala, A. N., Jaep, K. M., Gormley, R. P., Maue, A. C., Christmann, B. S., Elson, C. O., Riddle, M. S., & Porter, C. K. (2015) · Journal of Travel Medicine · doi:10.1111/jtm.12218 · Cited by 46
The Effect of Rifaximin on Gut Flora and Staphylococcus Resistance
Kim, M.-S., Morales, W., Hani, A. A., Kim, S. H., Kim, G. H., Weitsman, S. R., Chang, C. C.-C., & Pimentel, M. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2675-0 · Cited by 41
“In the study of IBS, the hypothesis is that small intestinal bacterial overgrowth may be important in this condition.”
BackgroundInfluentialSelf-citationPathophysiology of the irritable bowel syndrome – Reflections of today
Hellström, P. M. (2019) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2019.05.007 · Cited by 47
Yu, Z., Cen, Y.-X., Wu, B.-H., Cheng, W., Xiong, F., Li, D., Liu, T.-T., Luo, M., Guo, L., Li, Y., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3956 · Cited by 44
Лазебник, Л. Б., Голованова, Е. В., Volel, B. A., Korochanskaya, N. V., Lyalyukova, E. A., Мокшина, М. В., Насрединович, М. С., Мехтиева, О. А., Metsaeva, Z. V., Petelin, D. S., et al. (2021) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-192-8-5-117 · Cited by 50
Plasse, T. F., Barton, G., Davidson, E., Abramson, D., Kalfus, I., Fathi, R., Raday, G., & Harris, M. S. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000727 · Cited by 40
“The magnitude of effects was comparable with thosewith other approved products for IBS-D, alosetron (17,18), rifaximin (19), and eluxadoline (20) across all study end points.”
ResultAntibiotics for Irritable Bowel Syndrome: Rationale and Current Evidence
Sachdev, A. H., & Pimentel, M. (2012) · Current Gastroenterology Reports · doi:10.1007/s11894-012-0284-2 · Cited by 44
Self-citationIleocecal valve dysfunction in small intestinal bacterial overgrowth: A pilot study
Miller, L. S., Vegesna, A. K., Sampath, A. M., Prabhu, S., Kotapati, S. K., & Makipour, K. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i46.6801 · Cited by 40
Probiotics in Irritable Bowel Syndrome: The Science and the Evidence
Quigley, E. M. M. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000348 · Cited by 41
Putative mechanisms of kiwifruit on maintenance of normal gastrointestinal function
Bayer, S. B., Gearry, R. B., & Drummond, L. (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1327841 · Cited by 44
“, 2004), but also mediative, since both antibiotics (Pimentel et al., 2011) and probiotics”
BackgroundIrritable bowel syndrome: diagnosis and management
Masuy, I., Pannemans, J., & Tack, J. F. (2020) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.19.02640-0 · Cited by 49
Shah, E. D., Salwen‐Deremer, J. K., Gibson, P. R., Muir, J. G., Eswaran, S. L., & Chey, W. D. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.09.043 · Cited by 43
Self-citationEmerging Role of the Gut Microbiome in Irritable Bowel Syndrome
Singh, P., & Lembo, A. J. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.03.003 · Cited by 42
Self-citationGhoshal, U. C., Srivastava, D., Verma, A., & Misra, A. (2011) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2011.17.2.185 · Cited by 39
“signed phase 3, double-blind, placebo-controlled trials, IBS patients without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools.(13) However, the present case suggests that even constipation resulting from slow motility…”
Chang, M. S., Minaya, M. T., Cheng, J., Connor, B. A., Lewis, S. K., & Green, P. H. R. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1719-6 · Cited by 40
“given placebo [31].”
Gut microbiota and sirtuins in obesity-related inflammation and bowel dysfunction
Lakhan, S. E., & Kirchgessner, A. L. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-202 · Cited by 45
“Treatment with rifaximin (Xifaxan, Salix Pharmaceuticals, Morrisville, NC, USA), a nonsystemic rifamycinderived antibiotic that exhibits low gastrointestinal absorption while retaining potent antibacterial activity [51] for two weeks has recently been shown to provide significant relief of symptoms associated with IBS…”
BackgroundCui, J., Lin, Z., Tian, H., Yang, B. K., Zhao, D., Ye, C., Li, N., Qin, H., & Chen, Q. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.710452 · Cited by 41
“The exclusion criteria were as follows: (1) other chronic GI diseases; (2) fecal sample positive for enteropathogenic microorganisms; (3) positive screening for HIV, HBV, or HCV antibodies; (4) a history of surgical interventions in the GI region (except for appendectomy, hernia repair, cholecystectomy, and gynecologi…”
BackgroundBarberio, B., Savarino, E. V., Black, C. J., & Ford, A. C. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.08.025 · Cited by 44
Nee, J. W., & Lembo, A. J. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16625 · Cited by 51
Self-citationNevé, B. L., Posserud, I., Böhn, L., Guyonnet, D., Rondeau, P., Tillisch, K., Naliboff, B. D., Mayer, E. A., & Simrén, M. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.75 · Cited by 43
Management Strategies for Abdominal Bloating and Distension.
Foley, A., Burgell, R., Barrett, J. S., & Gibson, P. R. (2014) · Europe PMC (PubMed Central) · Cited by 44
Ghoshal, U. C., Sachdeva, S., Pratap, N., Karyampudi, A., Mustafa, U., Abraham, P., Bhatt, C. B., Chakravartty, K., Chaudhuri, S., Goyal, O., et al. (2023) · Indian Journal of Gastroenterology · doi:10.1007/s12664-022-01333-5 · Cited by 51
“Rifaximin has been proven to be effective in the treatment of non-C-IBS in a large clinical trial, which led to its approval by the Food and Drug Administration in the USA [137].”
BackgroundInfluentialRifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship
Gao, J., Gillilland, M. G., & Owyang, C. (2014) · Gut Microbes · doi:10.4161/gmic.32130 · Cited by 45
Schmulson, M., Bielsa, M. V., Carmona-Sánchez, R., Hernández, A., López-Colombo, A., Vidal, Y. L., Peláez-Luna, M., Remes-Troche, J. M., Tamayo, J. L., & Valdovinos, M. A. (2014) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2014.01.001 · Cited by 38
“They show that rifaximin at a dose of 550 mg TID for 14 days in patients with IBS-Non C by Rome II criteria resulted in a greater proportion of patients with adequate relief from IBS symptoms, abdominal bloating, daily symptom intensity, abdominal pain, and stool consistency.(134) In the follow-up at 10 weeks post-tre…”
InfluentialDembiński, A., Warzecha, Z., Ceranowicz, P., Dembiński, M., Cieszkowski, J., Gosiewski, T., Bulanda, M., Kuśnierz-Cabala, B., Gałązka, K., & Konturek, P. C. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/3126280 · Cited by 38
“…2 June 2016 Academic Editor: Sung-Ling Yeh Copyright © 2016 Artur Dembiński et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.”
MethodDiarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations
Lacy, B. E., & Moreau, J. C. (2016) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12387 · Cited by 43
“Compared with placebo, a significantly greater percentage of patients receiving rifaximin reported adequate relief of global IBS symptoms at 10 weeks posttreatment (p < .001, pooled analysis; Figure 3; Pimentel et al., 2011a).”
BackgroundAdvances in IBS 2016: A Review of Current and Emerging Data.
Jacobson, I. M. (2016) · PubMed · Cited by 59
Lacy, B. E. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14948 · Cited by 50
“001 [pooled data]).(54) In a phase 3, randomised, double‐blind, placebo‐controlled, multiple short‐course treatment trial published in 2016, repeat treatment with a 2‐week course of rifaximin 550 mg three times daily in”
BackgroundHong, G., Li, Y., Yang, M. J., Li, G., Qian, W., Xiong, H., Bai, T., Song, J., Zhang, L., & Hou, X. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13891 · Cited by 41
Functional Bowel Disorders in Adults
Häuser, W., Layer, P., Henningsen, P., & Kruis, W. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0083 · Cited by 48
Takakura, W., Rezaie, A. R., Chey, W. D., Wang, J., & Pimentel, M. (2024) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm22187 · Cited by 43
“7,8 Rifaximin appears to have a transient effect at reducing the relative abundance of certain taxa such as Enterobacteriaceae.”
BackgroundSelf-citationAndresen, V., Keller, J., Pehl, C., Schemann, M., Preiß, J., & Layer, P. (2011) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2011.0751 · Cited by 53
Mangel, A. W., & Hicks (2012) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s23274 · Cited by 39
“Rifaximin shows marginal eff icacy, with differences of rifaximin over placebo in the two pivotal studies of approximately 9% on the primary endpoint.(18,19) Evaluation of abdominal pain also showed benefit of less than a 10% difference with rifaximin as compared with placebo.”
BackgroundHuang, J. S., Jiang, Z., Garey, K. W., Lasco, T. M., & DuPont, H. L. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00548-13 · Cited by 37
“Rifaximin has been used to treat traveler’s diarrhea (9), CDI (10), diarrhea predominant irritable bowel syndrome (11), and hepatic encephalopathy (HE) (12).”
BackgroundUusijärvi, A., Bergström, A., Simrén, M., Ludvigsson, J. F., Kull, I., Wickman, M., Alm, J., & Olén, O. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12340 · Cited by 37
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
STOCKMAN, J. A. (2012) · Yearbook of Pediatrics · doi:10.1016/j.yped.2011.06.012 · Cited by 37
The Benefits of Yogurt, Cultures, and Fermentation
Freitas, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00024-0 · Cited by 49
Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases
DuPont, H. L. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.04.016 · Cited by 45
“In2 identically designed, randomized, double-blind, placebo-controlled clinical trials (TARGET 1 and 2; N1⁄41260), adults with a diagnosis and current symptoms of IBS without constipation were randomized to receive either rifaximin 550 mg thrice daily or placebo for 14 days.(35) The primary end point was adequate reli…”
BackgroundMethodMarlicz, W. M., Yung, D. E., Skonieczna‐Żydecka, K., Łoniewski, I., van Hemert, S., Łoniewska, B., & Koulaouzidis, A. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1343664 · Cited by 38
“Neomycin and rifaximin have improved symptoms in IBS patients, suggesting a link between the disorder and the SB ecosystem [159].”
BackgroundNoh, C., & Lee, K. J. (2020) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm20080 · Cited by 38
“However, studies have shown that the administration of rifaximin to patients with IBS without constipation improved IBS symptoms and bloating.(11) Similarly, administration of probiotics is reported to reduce the symptom severity of patients with functional abdominal bloating.”
Saps, M., & Miranda, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2016_119 · Cited by 42
Mechanisms of visceral pain in health and functional gastrointestinal disorders
Farmer, A. D., & Aziz, Q. (2014) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2014.01.002 · Cited by 43
“[85] Pimentel M, Lembo A, CheyWD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP, Group TS.”
Background"Red flag" evaluation yield in irritable bowel syndrome.
Black, T. P., Manolakis, C. S., & Palma, J. A. D. (2012) · PubMed · Cited by 35
Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome
Kane, J. S., & Ford, A. C. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1140571 · Cited by 36
“In Lembo et al. SAEs were seen in two individuals in the rifaximin group and three individuals in the placebo group [81].”
BackgroundInfluentialRivkin, A. M., & Rybalov, S. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1712 · Cited by 35
“The largest two identical phase III double-blind, placebo-controlled trials, TARGET 1 and TARGET 2, enrolled 1258 patients with IBS without constipation and were published in 2011.(19) The TARGET trials primarily enrolled white women who had IBS symptoms on average for 11– 12 years prior to study enrollment.”
BackgroundBiodiversity of the Genus Aspergillus in Different Habitats
Abdel-Azeem, A. M., Salem, F. M., Abdel-Azeem, M. A., Nafady, N. A., Mohesien, M. T., & Soliman, E. A. M. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-444-63505-1.00001-4 · Cited by 51
Shah, A., Gurusamy, S. R., Hansen, T. J., Callaghan, G., Talley, N. J., Koloski, N. A., Walker, M. M., Jones, M. P., Morrison, M., & Holtmann, G. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07149-1 · Cited by 39
Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials
Li, J., Zhu, W., Liu, W., Wu, Y., & Wu, B. (2016) · Medicine · doi:10.1097/md.0000000000002534 · Cited by 35
“described adequately in 2 of these studies.(24,27) Three of the selected RCTs reported adverse events, including abdominal pain, nausea, vomiting, and headache.”
BackgroundResultIrritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches
Camilleri, M., & Ford, A. C. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_102 · Cited by 40
Shah, E. D., Almario, C. V., Spiegel, B. M., & Chey, W. D. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000502 · Cited by 34
“Whether individuals with IBS-M on therapy respond more similarly to IBS-C (35) or IBS-D (36) remains unknown.”
BackgroundSelf-citationLee, J. S., Kim, S., Chun, Y. S., Chun, Y., Shin, S. Y., Choi, C. H., & Choi, H. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13830 · Cited by 39
Global Research Trends in Irritable Bowel Syndrome: A Bibliometric and Visualized Study
Zhang, T., Ma, X., Tian, W., Zhang, J., Wei, Y., Zhang, B., Wang, F., & Tang, X. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.922063 · Cited by 46
Pohl, D., Oudenhove, L. V., Törnblom, H., Nevé, B. L., Tack, J. F., & Simrén, M. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.034 · Cited by 36
Yau, Y. K., Su, Q., Xu, Z., Tang, W., Ching, J. Y. L., Mak, J. W. Y., Cheung, C. P., Fung, M., Ip, M., Chan, P. K. S., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17703 · Cited by 36
Inconsistent symptom clusters for functional gastrointestinal disorders in Asia: is Rome burning?
Holtmann, G., & Talley, N. J. (2018) · Gut · doi:10.1136/gutjnl-2017-314775 · Cited by 33
Tryptophan: ‘essential’ for the pathogenesis of irritable bowel syndrome?
Berstad, A., Raa, J., & Valeur, J. (2014) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2014.936034 · Cited by 35
“[48] Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y,”
BackgroundCorsetti, M., Akyüz, F., & Tack, J. F. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12616 · Cited by 32
Pharmacological agents currently in clinical trials for disorders in neurogastroenterology
Camilleri, M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70837 · Cited by 32
“Thus, rifaximin, a nonabsorbable antibiotic, was associated with adequate relief that was even documented for 10 weeks after cessation of treatment (34); however, stool consistency and number and urgency of bowel movements were not improved.”
Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis
Zhu, L.-P., Ma, Y.-T., Ye, S., & Shu, Z.-Q. (2018) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2018/2890465 · Cited by 31
Gastroduodenal “Dysbiosis”: a New Clinical Entity
Shah, A., Morrison, M., & Holtmann, G. (2018) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-018-0207-x · Cited by 32
Muraki, M., Fujiwara, Y., Machida, H., Okazaki, H., Sogawa, M., Yamagami, H., Tanigawa, T., Shiba, M., Watanabe, K., Tominaga, K., et al. (2014) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2014.880182 · Cited by 34
“Although rifaximin has been used for the treatment of SIBO [21] and several studies have confirmed the clinical efficacy of rifaximin in patients with IBS [22,23], no study exploring the effects of rifaximin on the prevention and treatment of NSAID-induced small intestinal damage has yet been reported.”
MethodMethodological issues in the study of intestinal microbiota in irritable bowel syndrome.
Taverniti, V., & Guglielmetti, S. (2014) · PubMed · doi:10.3748/wjg.v20.i27.8821 · Cited by 40
Pharmacologic Therapies in Gastrointestinal Diseases
Fox, R. K., & Muniraj, T. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.03.009 · Cited by 39
“After a 2-week course, the efficacy persisted for up to 12 weeks.(55)”
BackgroundBajaj, J. S., Barbara, G., DuPont, H. L., Mearin, F., Gasbarrini, A., & Tack, J. F. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.04.020 · Cited by 33
Antibiotics and Probiotics for Irritable Bowel Syndrome
Goodoory, V. C., & Ford, A. C. (2023) · Drugs · doi:10.1007/s40265-023-01871-y · Cited by 34
“In two RCTs of identical design, TARGET 1 and TARGET 2, 1260 patients with non-constipated Rome II-defined IBS were assigned to either rifaximin 550 mg or placebo three times per day for 2 weeks [44].”
BackgroundMethodGastrointestinal infections and the development of irritable bowel syndrome
DuPont, H. L. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32834a962d · Cited by 35
Breath Testing for Small Intestinal Bacterial Overgrowth: Should We Bother?
Pimentel, M. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.30 · Cited by 31
Self-citationAbdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
Lembo, A. J., Rao, S. S. C., Heimanson, Z., & Pimentel, M. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000144 · Cited by 36
Self-citationZyoud, S. H., Smale, S., Waring, W. S., Sweileh, W. M., & Al‐Jabi, S. W. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i13.1341 · Cited by 33
Sung, J. K., Morales, W., Kim, G., Pokkunuri, V. B., Weitsman, S. R., Rooks, E., Marsh, Z. A., Barlow, G. M., Chang, C., & Pimentel, M. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12118 · Cited by 38
Self-citationHigh-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome
Jolley (2011) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s18051 · Cited by 31
Halland, M., & Talley, N. J. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.207 · Cited by 40
Yu, J., Liu, T., Gao, Z., Liu, R., Wang, Z., Chen, Y., Cao, J., & Dong, Y. (2022) · Nutrients · doi:10.3390/nu14153164 · Cited by 31
“Previous studies have shown that antibiotic treatments and probiotics are beneficial to patients with intestinal diseases [6,7], suggesting that intestinal flora may play an important role in the pathogenesis of intestinal diseases.”
BackgroundSelf-citationPostinfectious Functional Gastrointestinal Disorders
Mearin, F. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31821fbf58 · Cited by 31
Pimentel, M., & Chang, C. C.-C. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.12.010 · Cited by 33
Self-citationBreckan, R. K., Asfeldt, A. M., Straume, B., Florholmen, J., & Paulssen, E. J. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.688215 · Cited by 32
“A study by Pimentel and co-workers showed that rifaximin had a positive effect on patients with IBSD [56] whereas a study by Morken and co-workers could not find an effect of antibiotics in patients with post-infectious IBS [57].”
BackgroundIBS and the role of otilonium bromide
Boeckxstaens, G. E., Corazziari, E. S., Mearin, F., & Tack, J. F. (2012) · International Journal of Colorectal Disease · doi:10.1007/s00384-012-1598-0 · Cited by 32
“In a recent RCT, the non-absorbable antibiotic rifaximin was superior to placebo at improving bloating, abdominal pain, and loose or watery stools [52].”
BackgroundMicrobiome, antibiotics and irritable bowel syndrome
Ahmad, O. F., & Akbar, A. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw038 · Cited by 29
“These effects were durable for the 10-week drug-free follow-up period.(61) A more recent third randomized, double-blind, placebo-controlled trial (TARGET 3) was conducted to assess the safety and efficacy of repeat treatment with rifaximin.”
BackgroundMethodInfluentialCash, B. D., Pimentel, M., Rao, S. S. C., Weinstock, L. B., Chang, L., Heimanson, Z., & Lembo, A. J. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17726087 · Cited by 33
Self-citationZhuang, X., Tian, Z., Luo, M., & Xiong, L. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01336-6 · Cited by 32
“In the well-known TARGET 1 and TARGET II studies, only 40% of patients responded to rifaximin, but treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms including bloating, abdominal pain, and loose or watery stools [28].”
MethodDietary modulation of gut microbiota for the relief of irritable bowel syndrome
Kim, M.-Y., & Choi, S. (2021) · Nutrition Research and Practice · doi:10.4162/nrp.2021.15.4.411 · Cited by 30
Approach to the Patient with Gastrointestinal Disease
McQuaid, K. R. (2012) · Goldman's Cecil Medicine · doi:10.1016/b978-1-4377-1604-7.00134-2 · Cited by 30
Schmulson, M., Bielsa, M. V., Carmona-Sánchez, R., Hernández, A., López-Colombo, A., López Vidal, Y., Peláez-Luna, M., Remes-Troche, J. M., Tamayo, J. L., & Valdovinos, M. A. (2014) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2014.01.004 · Cited by 29
Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview
Bokic, T., Storr, M., & Schicho, R. (2015) · Pharmacology · doi:10.1159/000435816 · Cited by 33
Effect of a low‐flatulogenic diet in patients with flatulence and functional digestive symptoms
Azpiroz, F., Hernandez, C., Guyonnet, D., Accarino, A. M., Santos, J., Malagelada, J., & Guarner, F. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12324 · Cited by 34
Metadata
- Authors
- Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Michigan Medicine (US)
- Bristol Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Salix Pharmaceuticals (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 22-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149216059
- Cited by
- 1,036
- References
- 21
- Citations by year
- 2026: 51 · 2025: 46 · 2024: 36 · 2023: 56 · 2022: 51 · 2021: 65 · 2020: 56 · 2019: 51 · 2018: 65 · 2017: 74 · 2016: 87 · 2015: 70 · 2014: 95 · 2013: 73 · 2012: 87
- FWCI
- 106.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- rifaximin, gut microbiota, bloating, abdominal pain, stool consistency, symptom relief, antibiotic therapy, IBS pathophysiology, TARGET trial, adverse events
- MeSH terms
- Rifaximin, Aged, Anti-Bacterial Agents, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Rifamycins, Abdominal Pain, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.